• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

A Look at Psychedelics in the Media

Jason Najum by Jason Najum
July 6, 2022
in Culture, Industry
Reading Time: 3 mins read
A A
A Look at Psychedelics in the Media

The movement to get psychedelic medicine into the mainstream requires action on multiple fronts. Commercial development, FDA approval, and regulatory changes are all necessary pieces of the puzzle, each doing their part in changing minds and moving the needle towards greater acceptance.

But then there’s the media, our print and digital puppet-masters, pulling the strings and tipping the scales of public opinion. It could be argued that all other aspects — laws, drug approval etc — are dependent on what the media has to say on the subject. Positive coverage leads to positive public opinion which leads to the people in decision making roles being more likely to sign that paper and make that change a reality.

So let’s take a look at recent psychedelic medicine headlines and see what the media has been saying as of late.

 

[bsa_pro_ad_space id=2]
ADVERTISEMENT

 

Continue on your trip...

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

The New York Times: Can MDMA Save a Marriage?

“For some couples on the brink of divorce, taking the illegal psychedelic drug was a last resort — but it ended up being the only thing that worked.”

 

Rolling Stone: How an NHL Enforcer Broke His Body — and Turned to Psychedelics to Heal His Brain

“Over eight years playing pro hockey, Riley Cote suffered countless blows to the head. Now he’s preaching the power of psilocybin to help treat the effects.”

 

The Economist: Bosses want to feed psychedelics to their staff

“A growing number of firms want to offer psychedelics to staff, either for the sake of mental health or to organise a mind-bending corporate retreat.”

 

CNN: How psilocybin, the psychedelic in mushrooms, may rewire the brain to ease depression, anxiety and more

Affordable Lasix Purchase

“Small clinical trials that have shown that one or two doses of psilocybin, given in a therapeutic setting, can make dramatic and long-lasting changes in people suffering from treatment-resistant major depressive disorder, which typically does not respond to traditional antidepressants.”

[bsa_pro_ad_space id=2]
ADVERTISEMENT

 

Psychology Today: Psychedelics Give a Glimpse of Enlightenment

“Our brains may be filters that are inhibiting us from experiencing reality.”

 

The New York Times: The Next Big Addiction Treatment

“Several psychedelic drugs are touted as effective treatments for drug and alcohol abuse. But psilocybin combined with therapy is emerging as the most effective.”

 

The Economist: Is ketamine the answer for treatment-resistant depression?

“Podcast on science and technology. This week, we explore the growing number of clinics offering the anaesthetic—also used illegally as a party drug—as a treatment for mental health-conditions.”

 

Interested in more like this? Check out Michael Pollan Psychedelics Documentary to Launch on Netflix

Tags: News
Jason Najum

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Next Post
Roth Capital Doubles Down on Cybin After DMT Acquisition

Psychedelic Stocks: Have We Finally Hit Bottom?

Please login to join discussion

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.